



Brighton and Hove Clinical Commissioning Group  
 High Weald Lewes Havens Clinical Commissioning Group  
 Brighton and Sussex University Hospitals NHS Trust

**JOINT FORMULARY  
 APPENDIX 3 – BLACKLIST**  
[Formulary home page](#)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)**

<a href="#">A3.1</a>	Gastro-intestinal
<a href="#">A3.2</a>	Cardiovascular
<a href="#">A3.3</a>	Respiratory
<a href="#">A3.4</a>	CNS
<a href="#">A3.5</a>	Infections
<a href="#">A3.6</a>	Endocrine
<a href="#">A3.7</a>	Gynae and urinary tract
<a href="#">A3.8</a>	Malignant Disease and Immunosuppression
<a href="#">A3.9</a>	Nutrition and Blood
<a href="#">A3.10</a>	Musculoskeletal
<a href="#">A3.11</a>	Eye
<a href="#">A3.12</a>	ENT
<a href="#">A3.13</a>	Skin
<a href="#">A3.X</a>	Medical Devices and Miscellaneous

**This list also extends to any items**

- Which are included in the National Blacklist (not permitted on an NHS prescription). Found here in the [Drug Tariff Part XVIII A - Drugs, Medicines and Other Substances not to be ordered under a General Medical Services Contract](#)
- Which have a negative or terminated NICE TA or are included in the NICE [Do Not Do/Do Not Do recommendation list](#)

**Version Control**

Date of revision	Sections reviewed	Contributors
08.2014	Initial production	Dr S Glaspole and Jade Tomes
11.2014	Clinical review	APC
07.2017	APC review - all sections	APC and BSUH

Ctrl-f will activate the search window.

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
 UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

Drug Name	Formulation	Comments
<b>A3.1 Gastro-intestinal (<a href="#">Back To Top</a>)</b>		
<b>A3.1.1.2 Compound alginates and proprietary indigestion preparations</b>		
Gaviscon Advance®	Tablets chewable sodium alginate 500 mg, potassium bicarbonate 100 mg	
<b>A3.1.2 Antispasmodics and other drugs altering gut motility</b>		
Colofac®	Tablets 135mg	Branded prescribing not funded on the local NHS.
<b>A3.1.3.5 Proton pump inhibitors</b>		
Nexium®	Tablets 20mg, 40mg	Branded prescribing not funded on the local NHS.
Losec®	Capsules 10mg, 20mg, 40mg	Branded prescribing not funded on the local NHS.
<b>A3.1.4.3 Enkephalinase inhibitors</b>		
Racecadotril	Capsules 100 mg Granules 10 mg per sachet	
<b>A3.1.5.1</b>		
Asacol®	Tablets e/c 400mg, 800mg	Branded prescribing not funded on the local NHS.
<b>A3.1.6 Laxatives</b>		
Aralax®	Suppositories bisacodyl 7.5mg	
Movicol®	Oral powder, macrogol 3350	Branded prescribing not funded on the local NHS.
<b>A3.2 Cardiovascular (<a href="#">Back To Top</a>)</b>		
RESPeRATE®	Device for lowering blood pressure	
Omega 3	All formulations	Not to be prescribed for: Post MI
<b>A3.2.5.4 Alpha-adrenoceptor blocking drugs</b>		
Doxazosin	Tablets MR 4mg, 8mg	
<b>A3.2.5.5.1 Angiotensin-converting enzyme inhibitors</b>		
Perindopril arginine	Tablets 2.5mg, 5mg, 10mg	Coversyl arginine®.
Perindopril arginine with indapamide	Tablets 5mg / 1.25mg, 10mg	Coversyl arginine Plus®.
<b>A3.2.5.5.3 Renin inhibitors</b>		
Aliskiren	Tablets 150mg, 300mg	<a href="#">Included in the items which should not be routinely prescribed in primary care: Guidance for CCG's, 2019 update</a>
<b>A3.2.9 Antiplatelet drugs</b>		
Plavix®	Tablets 75mg, 300mg	Branded prescribing not funded on the local NHS.
<b>A3.2.12 Lipid-regulating drugs</b>		
Lipitor®	Tablets 10mg, 20mg, 40mg, 80mg	Branded prescribing not funded on the local NHS.

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>A3.3 Respiratory (<a href="#">Back To Top</a>)</b>		
iNeb®-ADD consumables	Products/nebules for this device are not routinely available	<u>Excluding tobramycin.</u> See JF <a href="#">Chapter 5</a> for approved indications/ commissioning responsibilities
<b>A3.3.1.1.1 Selective beta2 agonists</b>		
Indacaterol	Inhalation powder, hard capsule (for use with Onbrez Breezhaler® device), 150 micrograms, 300 micrograms	
<b>A3.4.2 Allergen immunotherapy</b>		
Grazax®	Oral lyophilisates containing grass pollen extract 75 000 units.	Not supported due to the modest size of the effects, the absence of any published comparisons with established symptomatic treatments or with subcutaneous immunotherapy and because of its high cost.
<b>A3.3.7 Mucolytics</b>		
Mucodyne®	Capsules 375mg	Branded prescribing not funded on the local NHS.
<b>A3.4 CNS (<a href="#">Back To Top</a>)</b>		
<b>A3.4.1 Hypnotics and anxiolytics</b>		
Melatonin	All formulations	Not to be prescribed for: the prevention of Jet-lag
Diazepam	Tablets 2 mg,5 mg,10 mg Oral Solution 2 mg in 5 ml and 5 mg in 5 ml Injection (Diazemuls®) 10mg/2 ml	Not to be prescribed for: the fear of flying. See <a href="#">Overseas Travel Guidance</a>
<b>A3.4.2.1 Antipsychotic drugs</b>		
Abilify®	Tablets 5mg, 10mg, 15mg, 30mg	Branded prescribing not funded on the local NHS.
Loxapine	Inhalation	Not to be prescribed for: bipolar or schizophrenia
<b>A3.4.3 Antidepressant drugs</b>		
Lustral®	Tablets 50mg, 100mg	Branded prescribing not funded on the local NHS.
Dosulepin	Capsules 25mg Tablets 75mg	No new initiations from March 18.
Trimipramine	Capsules 50mg Tablets 10mg, 25mg	
<b>A3.4.3.4 Other antidepressant drugs</b>		
Cymbalta®	Capsules 30mg, 60mg	Branded prescribing not funded on the local NHS.
Effexor®	Capsules 75mg, 150mg	Branded prescribing not funded on the local NHS.
<b>A3.4.7.1 Non-opioid analgesics and compound analgesic preparations</b>		
Co-proxamol	Tablets containing paracetamol and dextropropoxyphene hydrochloride	Withdrawn from market. <a href="#">MHRA guidance</a>
Paracetamol with tramadol	Tablets 37.5mg / 325mg Effervescent tablets 37.5mg / 325mg	Tramacet®

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>A3.4.7.2 Opioid analgesics</b>		
Fentanyl	Tablets (sublingual) 100, 133, 200, 267, 300, 400, 533, 600, 800 micrograms Tablets (buccal) 100, 200, 400, 600, 800 micrograms Lozenge (buccal) 200, 400, 600, 800 micrograms Film (buccal) 200, 400, 800 micrograms Nasal spray (All strengths)	No new initiations from March 18 for non-palliative care indications.
Oxycodone with naloxone	Tablets f/c, MR 5mg / 2.5mg, 10mg / 5mg, 20mg / 10mg, 40mg / 20mg	Targinact® No new initiations from March 18.

<b>A3.4.7.4.1 Treatment of acute migraine</b>		
Imigran®	Tablets 50mg, 100mg	Branded prescribing not funded on the local NHS.
Maxalt®	Tablets 5mg, 10mg	Branded prescribing not funded on the local NHS.

<b>A3.4.9.1 Dopaminergic drugs used in Parkinson's disease</b>		
Azilect®	Tablets 1mg	Branded prescribing not funded on the local NHS.

<b>A3.4.10.3 Opioid dependence</b>		
Subutex®	Tablets sublingual 400mcg, 2mg, 8mg	Branded prescribing not funded on the local NHS.
Naltrexone	4.5mg, 3mg and 1.5mg capsules and liquids at low dose for Multiple Sclerosis	Not supported due to limited evidence to support safety and efficacy. Unlicensed in MS and requires ordering as a "specials" product which represents a significant cost. Not approved for MS by the MHRA "Currently there is not enough evidence-based information to prove LDN is an effective treatment for MS"
Fish oil supplements	All formulations	Not to be prescribed for: ADHD (children), behavioural problems, learning difficulties.
Omega-3	All formulations	

## **A3.5 Infections ([Back To Top](#))**

<b>5.1.3 Tetracyclines</b>		
Tetralysal®	Capsules 300mg	Branded prescribing not funded on the local NHS.
Minocycline	Capsules 50mg, 100mg M/R capsules 100mg Tablets 50mg, 100mg	<a href="#">Included in the items which should not be routinely prescribed in primary care: Guidance for CCG's, 2019 update</a>

<b>A3.5.1.7 Some other antibacterials</b>		
Rifaximin	Tablets 200 mg	Not to be prescribed for: stand-by or preventative treatment for travellers' diarrhoea.

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>A3.5.4.1 Antimalarials</b>		
All antimalarials for prophylaxis	These are not prescribable on the NHS. Patients can obtain a supply on private prescription or purchase OTC from Community Pharmacies for non POM medicines	

<b>A3.6 Endocrine (<a href="#">Back To Top</a>)</b>		
Intrinsa <sup>®</sup> Patches		MA withdrawn
Progest <sup>®</sup> or Pro-Juven <sup>®</sup> cream		
Armour <sup>®</sup> thyroid	The British Thyroid Association (BTA) Executive Committee states 'There is no evidence to favour the prescription of Armour Thyroid in the treatment of hypothyroidism over the prescription of thyroxine sodium, as supplied in the United Kingdom. There has never been a direct comparison of these two treatments.	
Liothyronine	For long-term thyroid replacement is not within license and therefore not supported. See <a href="#">Information for patients currently treated with T3 from BSUH Sept 2016</a>	
<b>A3.6.1.1.2 Intermediate- and long-acting insulins</b>		
<b>A3.6.1.1.3 Hypodermic equipment</b>		
Pen needles	All brands of pen needles costing >£3 / 100 are not funded on the local NHS	
<b>A3.6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens</b>		
<b>A3.6.6.2 Bisphosphonates and other drugs affecting bone metabolism</b>		
Alendronic acid with Colecalciferol	Tablets alendronic acid 70mg and colecalciferol 70 micrograms (2800 units)	(Fosavance <sup>®</sup> )
	Tablets alendronic acid 70mg and colecalciferol 140 microgram (5600 units)	(Bentexo <sup>®</sup> )

<b>A3.7 Gynae and urinary tract (<a href="#">Back To Top</a>)</b>		
IVF drugs	All local NHS-funded infertility treatments include the prescribing of drugs by the NHS specialist. Local contract arrangement for Prescribing of Progesterone (i.e., Gestone) is undertaken for 1 week following a positive pregnancy test, and then the remaining 7 weeks of prescribing is expected to be undertaken by the female partner's GP, in line with general maternity related prescribing.	
<b>A3.7.3.2 Oral progestogen-only contraceptives</b>		
Cerazette	Tablets 75micrograms	Branded prescribing not funded on the local NHS.
Cerelle	Tablets 75micrograms	Branded prescribing not funded on the local NHS.
Norethisterone	Tablets 5mg	Not to be prescribed for: postponement of menstruation for e.g. a holiday or event. See <a href="#">Overseas Travel Guidance</a>
Medroxyprogesterone acetate	Tablets 5mg, 10mg	Not to be prescribed for: postponement of menstruation for e.g. a holiday or event. See <a href="#">Overseas Travel Guidance</a>

**If further supporting information is required please contact your CCGs medicines management team:**  
For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)  
For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>A3.7.4.5 Drugs for erectile dysfunction</b>		
Viagra®	Tablets 25mg, 50mg, 100mg	Branded prescribing not funded on the local NHS.
Tadalafil	Tablets 2.5mg, 5mg	Cialis®
Alprostadil	Use of both oral and non-oral (creams, injections) combination treatments for erectile dysfunction in patients who had not responded/had a sub-optimal response to mono-therapy is not supported.	<a href="#">Erectile Dysfunction Pathway in Primary Care</a>
Sildenafil		
Tadalafil		
Vardenafil		
Vacuum erection devices		

**A3.8 Malignant Disease and Immunosuppression** ([Back To Top](#))  
 This section includes any drugs which have a negative NICE TA or are included in the NICE [Do Not Do/Do Not Do recommendation list](#)

<b>A3.8.3.4.1 Breast cancer</b>		
Arimidex	Tablets 1mg	Branded prescribing not funded on the local NHS.

**A3.9 Nutrition and Blood** ([Back To Top](#))

**A3.9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias**

Siklos®	Hydroxycarbamide Tablets 100 mg	
---------	---------------------------------	--

**A3.9.1.4 Drugs used in platelet disorders**

**A3.9.4.1 Foods for special diets**

Sapropterin dihydrochloride	Dispersible tablets 100 mg	
-----------------------------	----------------------------	--

**A3.9.5.2.2 Phosphate-binding agents**

Renagel®	Tablets 800mg	Branded prescribing not funded on the local NHS.
----------	---------------	--

**A3.9.6.2 Vitamin B**

Vitamin B Compound Strong and Vitamin B Compound	Tablets	All indications apart from refeeding syndrome. (This includes use in ETOH detox.)
--	---------	---

**A3.10 Musculoskeletal** ([Back To Top](#))

**A3.10.1 Drugs used in rheumatic diseases and gout**

Hyaluronic acid	Synvisc®, Hyalgan®, Durolane®.	
-----------------	--------------------------------	--

**A3.10.1.1 Non-steroidal anti-inflammatory drugs**

Diclofenac with misoprostil	Arthrotec® 50 tablets, diclofenac sodium (in e/c core) 50 mg, misoprostol 200 micrograms Arthrotec® 75 tablets, diclofenac sodium (in e/c core) 75 mg, misoprostol 200 micrograms Misofen® Tablets, diclofenac sodium (in e/c core) 50 mg, misoprostol 200 micrograms Misofen® Tablets, diclofenac sodium (in e/c core) 75 mg, misoprostol 200 micrograms	
Naproxen with esomeprazole	M/R Tablets naproxen 500 mg, esomeprazole 20 mg	

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
 UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>A3.10.1.3 Drugs which suppress the rheumatic disease process</b>		
Infliximab	Powder for reconstitution, 100mg vial, for IV infusion	Not supported for use in ankylosing spondylitis.

<b>A3.10.1.4 Gout and cytotoxic-induced hyperuricaemia</b>		
--	--	--

Pegloticase		
-------------	--	--

<b>A3.10.1.5 Other drugs for rheumatic diseases</b>		
---	--	--

Glucosamine (All strengths and preparations)	Glucosamine has been subject to evaluation by NICE, the SMC and the Drugs & Therapeutics Bulletin which concluded lack of efficacy. Whilst evidence of benefit is minimal, there is little evidence of harm and if patients wish to purchase the product directly, they should be advised to purchase an over-the-counter product containing glucosamine sulphate.	
Chondroitin (All strengths and preparations)		

<b>A3.10.2.2 Skeletal muscle relaxants</b>		
--	--	--

Cannabis Extract (Sativex®)	Oromucosal spray containing dronabinol (delta-9-tetrahydrocannabinol) 27 mg and cannabidiol 25 mg/mL	<b>NICE CG</b> on MS states: "Do not offer Sativex to treat spasticity in people with MS because it is not a cost effective treatment"
-----------------------------	--	--

<b>A3.10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices</b>		
---	--	--

Rubefacients	All products (gels, creams, rubs, sprays ointments etc. e.g. Deep freeze/heat, Difflam, Mentholatum, Movelat, Radian B, Ralgex.) including capsaicin cream 0.025% (Zacin®)	No new initiations from March 18 except for Algesal cream
Capsaicin	Patches 179 mg	

<b>A3.11 Eye (<a href="#">Back To Top</a>)</b>		
--	--	--

Eye supplements for ocular health	E.g. ICaps®, Ocuville®, PreserVision®	<a href="#">Macular Society's Nutrition and your eyes PIL</a>
Blephaclean®, Blephasol® or similar eyelid wipes / solution		<a href="#">CKS guidance on eye hygiene</a>

<b>A3.11.6 Treatment of glaucoma</b>		
--------------------------------------	--	--

Azopt®	10mg / ml eye drops	Branded prescribing not funded on the local NHS.
Xalatan®	50mcg / ml eye drops	Branded prescribing not funded on the local NHS.
Xalacom®	50mcg latanoprost / 5mg timolol / ml eye drops	Branded prescribing not funded on the local NHS.
Cosopt®	2% dorzolamide / 0.5% timolol eye drops	Branded prescribing not funded on the local NHS.

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrcgg.esifrs@nhs.net](mailto:hrcgg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>A3.12 ENT (<a href="#">Back To Top</a>)</b>		
<b>A3.12.2.1 Drugs used in nasal allergy</b>		
Fluticasone propionate & Azelastine hydrochloride (Dymista®)	Nasal spray, fluticasone propionate 50 micrograms and azelastine hydrochloride 137 micrograms per spray	
Nasonex®	Nasal spray 50mcg	Branded prescribing not funded on the local NHS.
Beconase®	Nasal spray 50mcg	Branded prescribing not funded on the local NHS.
<b>A3.13 Skin (<a href="#">Back To Top</a>)</b>		
<b>A3.13.2.1 Emollients</b>		
Diprobase	Cream containing cetomacrogol 2.25%, cetostearyl alcohol 7.2%, liquid paraffin 6%, white soft paraffin 15%. Ointment containing liquid paraffin 5%, white soft paraffin 95%.	Approved formulary alternative is Zerobase.
Doublebase	Gel containing Isopropyl Myristate 15% and Liquid Paraffin 15% w/w	Approved formulary alternative is Zerodouble
E45	Cream containing light liquid paraffin 12.6%, white soft paraffin 14.5%, hypoallergenic anhydrous wool fat (hypoallergenic lanolin) 1% in self-emulsifying monostearin. Lotion containing light liquid paraffin 4%, cetomacrogol, white soft paraffin 10%, hypoallergenic anhydrous wool fat (hypoallergenic lanolin) 1% in glyceryl monostearate	Approved formulary alternative is Zerocream
<b>A3.13.2.1.1 Emollient bath and shower preparations</b>		
All bath and shower preparations	e.g. Allergenis, Aquamax, Aveeno, Balneum, Cetraben, Dermal, Diprobath, Doublebath, Doublebase, Eurax, E45, Hydromol, LPL 63.4, Oilatum, Oilatum Plus, QV, Skin Salvation, Zerolatum, Zerolatum Plus	This list is not exhaustive.
<b>A3.13.4 Topical corticosteroids</b>		
Elocon®	Ointment, Cream	Branded prescribing not funded on the local NHS.
<b>A3.13.6.3 Topical preparations for rosacea</b>		
Brimonidine tartrate Gel (Mirvaso®)	Gel containing brimonidine tartrate 5 mg/g	
<b>A3.13.7 Preparations for warts and calluses</b>		
Imiquimod (Zyclara®)	Cream 3.75% (sachets)	For actinic keratosis
<b>A3.13.9 Shampoos and other preparations for scalp and hair conditions</b>		
Eflornithine	Cream containing Eflornithine 11.5%	
<b>A3.13.10.3 Antiviral preparations</b>		
Molludab®	Potassium hydroxide 5% solution	
Molutrex®	Potassium hydroxide 5% solution	
<b>A3.13.11.6 Oxidisers and dyes</b>		
Crystacide®	Cream containing hydrogen peroxide 1%	

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.



<b>A3.13.12 Antiperspirants</b>		
Glycopyrronium bromide	All oral preparations	Expect for use in hypersalivation where other antimuscarinic treatments have failed or patient intolerant due to side effects. See <a href="#">Chapter 4</a> in the joint formulary.

**A3.14 Immunological products and vaccines** ([Back To Top](#))

**A3.14.4 Vaccines and antisera**

Varicella–zoster vaccine	Injection powder for reconstitution, live attenuated varicella–zoster virus (Oka/Merck strain) propagated in human diploid cells	Those eligible for immunisation: Patients aged 70 or 78. <u>Additional cohorts</u> Patients in their 70s who were born after 1 September 1942 and patients aged 79.
--------------------------	--	--

Travel Vaccines	<p>The following vaccinations should not be prescribed on the NHS exclusively for the purposes of travel:</p> <ul style="list-style-type: none"> <li>• Hepatitis B</li> <li>• Japanese Encephalitis</li> <li>• Meningitis ACWY</li> <li>• Yellow Fever</li> <li>• Tick-borne encephalitis</li> <li>• Rabies</li> <li>• BCG</li> </ul> <p><b>These vaccines should continue to be recommended for travel but the individual traveller will need to bear the cost of the vaccination.</b></p> <p>To note the following vaccines may still be administered on the NHS exclusively for the purposes of travel, if clinically appropriate, pending any future review:</p> <ul style="list-style-type: none"> <li>• Cholera</li> <li>• Diphtheria/Tetanus/Polio</li> <li>• Hepatitis A</li> <li>• Typhoid</li> </ul>	
-----------------	--	--

**A3.15 Anaesthesia** ([Back To Top](#))

**A3.15.2 Local anaesthesia**

Lidocaine	Plasters 5%	No new initiations from March 18
-----------	-------------	----------------------------------

*If further supporting information is required please contact your CCGs medicines management team:*

*For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)*

*For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)*

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>A3.X Medical devices and Miscellaneous (<a href="#">Back To Top</a>)</b>	
<b>Medical devices - not routinely commissioned and detailed in the <a href="#">PrescQIPP DROP-list</a> are included in this section. <sup>1</sup>Devices not routinely commissioned after local consideration.</b>	
Aknicare <sup>®</sup> cream and lotion, aknicare <sup>®</sup> sr skin roller	Not recommended for prescribing. Those who wish to try Aknicare <sup>®</sup> products should be directed to purchase them for self-care. They should however be advised that benzoyl peroxide-containing OTC products are generally preferred because of the substantial clinical trial evidence to support their use.
Otovent <sup>®</sup> ADULTS	Adults wishing to use the device to equalise the air pressure in the middle ear, e.g. for air travel, can purchase the device for self-care.
Prontoderm <sup>®</sup> foam and Prontoderm <sup>®</sup> nasal gel	Not recommended for routine use; current randomised controlled trial evidence is limited and suggests that a single Prontoderm <sup>®</sup> decolonisation course is not effective in eradicating methicillin-resistant staphylococcus aureus (MRSA) carriage.
Belladonna adhesive plaster	Not recommended; there is insufficient evidence to recommend the use of belladonna adhesive plasters. Prescribing on FP10 should be discontinued. Those prescribed belladonna adhesive plasters should have their therapy reviewed. Consider recommending or prescribing an effective alternative treatment if appropriate. Do not initiate new prescriptions for belladonna adhesive plasters.
Vibro-pulse <sup>®</sup> Accessories	Not recommended; there is currently insufficient evidence to recommend the use of cycloidal vibration therapy.
Deodorants (stoma)	Not recommended for routine use; deodorants should not be required. If correctly fitted, no odour should be apparent except when bag is emptied or changed. Household air-fresheners are sufficient in most cases and are widely available to buy. If odour is present at times other than changing or emptying, refer the individual for review. Do not add to repeat prescribing systems.
Accel-heal <sup>®</sup>	Not recommended; there is currently insufficient evidence to recommend the use of the Accel-Heal <sup>®</sup> electrical stimulating device.
Eye compress	Not recommended; there is no evidence of additional benefit compared to using a clean flannel and warm water as an eye compress. Those that find commercially available eye compresses more convenient to use may purchase them from a pharmacy or on-line.
Head lice treatment devices	Treatments for head lice should be purchased for self care, or obtained via NHS minor ailments schemes through participating community pharmacies.
Insert for female stress incontinence	Not recommended; there is currently insufficient evidence to recommend the use of the Contiform <sup>®</sup> device, or other intravaginal or intraurethral devices for female stress incontinence. NICE do not recommend their routine use.
Saline nasal sprays, e.g. Sterimar <sup>®</sup> , Aqua maris <sup>®</sup>	Not recommended; limited evidence favours a different treatment.
Ostomy Underwear	Not recommended for routine use; Specific ostomy underwear for general use is not evidence based.
Pelvic toning devices	Not recommended; there is no evidence of additional benefit compared to undertaking pelvic floor exercises alone. Those that wish to use pelvic toning devices may purchase them from a pharmacy or on-line.

**If further supporting information is required please contact your CCGs medicines management team:**

**For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)**

**For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)**

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

**BH CCG: for further information click [here](#)**

**HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)**

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>Medical devices continued - not routinely commissioned and detailed in the <a href="#">PrescQIPP DROP-list</a> are included in this section. <sup>1</sup>Devices not routinely commissioned after local consideration.</b>	
Potassium hydroxide solution (For treating molluscum contagiosum)	Not recommended in primary care; there is currently insufficient evidence of efficacy and a risk of side-effects.
RESPeRATE <sup>®</sup> <sup>1</sup>	Device for lowering blood pressure.
Electronic cigarettes	e.g. Voke, e-Voke see <a href="#">PrescQIPP guidance statement</a>

<b>Miscellaneous</b>	
Silicone keloid dressing	
Co-enzyme Q10	
Probiotics	
Acidophilus	
DHEA	
Silk Garments	Poor evidence base – not appropriate to use NHS resources to prescribe these products.
Luxury Gluten Free Items	<a href="#">BH G/F Prescribing Guidance</a> <a href="#">HWLH G/F Prescribing Guidance</a> Only bread and flour are routinely available.
Eye-Q	
Gamolenic acid	
Cod Liver Oil	
Health tonics e.g. Spa-Tone <sup>®</sup>	
ACBS preps where used in non ACBS indications e.g. soya milks, sun creams	Infant soya milk is a borderline substance which can only be prescribed in the case of lactose intolerance. Disadvantages of soya milk: 1. lactose is replaced with glucose, which has been shown to damage developing teeth 2. soya milk contains phytoestrogens. The effect of these on development is not fully understood Sunscreens specified in the Drug Tariff (Part XV) and the latest BNF can only be prescribed on an FP10 prescription, using an ACBS endorsement, for: Genetic disease causing skin excessively vulnerable to sun damage; Photodermatoses; Post radiotherapy treatment and Chronic or recurrent herpes simplex labialis. Sunscreens should not be prescribed on an NHS prescription for any other group.
Souvenaid <sup>®</sup>	Robust evidence to support the use of this product is lacking.
Homeopathy preparations	These are not licensed Drugs under the Medicines Act, so there is no approved summary of product characteristics (SmPC) for prescribers to consult. (N.B. prescribers are only indemnified by a drug company if there is an SmPC and if the drug is used within licensed indications) These products also lack either sufficient data on efficacy, safety and quality.
Alternative skin preparations e.g. Pure Potions <sup>®</sup>	
Elena's Skin Product <sup>®</sup>	
Bio-oil <sup>®</sup>	
Anthroposophic preparations e.g. Iscador	
Herbal products e.g. Ginkgo Biloba, St John's Wort	

**If further supporting information is required please contact your CCGs medicines management team:**

For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)

For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

BH CCG: for further information click [here](#)

HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.

<b>Miscellaneous continued</b>	
Thick & Easy®	These thickeners are starch-based. Evidence shows that amylase in saliva breaks down the molecular bonds in starch-based thickened drinks, causing these to become thin. This can cause drinks to separate if saliva enters the cup, causing a dangerous top thin layer of the drink. Starch-based thickened drinks may also be broken down by amylase along the oropharyngeal tract as they are swallowed, particularly in patients with oral holding/delayed swallow. This means that the drink may not be the required consistency as prescribed by the Speech & Language Therapist, placing the patient at risk of aspiration of thin fluids with subsequent risk of aspiration-related chest infection.
Thicken Aid	
Thixo D	
Multi-Thick	
Resource® Thicken-Up	

DO NOT PRESCRIBE

***If further supporting information is required please contact your CCGs medicines management team:***

*For B&H registered patients please direct any queries to: [BHCCG.MedicinesManagement@nhs.net](mailto:BHCCG.MedicinesManagement@nhs.net)*

*For HWLH registered patients please direct any queries to: [hwlhccg.mmt@nhs.net](mailto:hwlhccg.mmt@nhs.net)*

**THESE ITEMS ARE NOT FOR ROUTINE PRESCRIBING (BLACK)  
UNLESS APPROVED THROUGH THE IFR PROCESS**

**BH CCG: for further information click [here](#)**

**HWLH CCG: for further information email- [hrccg.esifrs@nhs.net](mailto:hrccg.esifrs@nhs.net)**

Adapted from The Surrey Prescribing Advisory Database ('PAD') and Drugs Not for Routine Prescribing document.